The desperate hunt for treatments and vaccines has changed how researchers, regulators, drug companies like Moderna, investors and journalists do their jobs.
Tag: Gilead Sciences Inc
How Remdesivir, New Hope for Covid-19 Patients, Was Resurrected
The drug failed as a treatment for hepatitis and Ebola. With federal funding, scientists trained it on the coronavirus.
Remdesivir Shows Modest Benefits in Coronavirus Trial
Hope soared nonetheless. The F.D.A. is likely to issue an emergency approval, a senior official said.
At the Center of a Storm: The Search for a Proven Coronavirus Treatment
Taking an experimental drug can be worse than taking nothing at all, warns Dr. Andre Kalil: “You are treating emotion.”
Coronavirus Patients in Limbo as Gilead Suspends Emergency Drug Access
The company says it will switch to a broader approach for its experimental drug, remdesivir. But it was overwhelmed by demand for a potential treatment promoted by President Trump.
Gilead to Expand Coronavirus Drug Trials to Other Countries
The drug maker said that in March it would begin two more clinical trials of remdesivir, an experimental antiviral drug, in more nations outside China.
Who Owns H.I.V.-Prevention Drugs? The Taxpayers, U.S. Says
In an unexpected lawsuit, federal officials claim that Gilead Sciences willfully disregarded government patents on medicines necessary to end the AIDS epidemic.
A Cure for Ebola? Two New Treatments Prove Highly Effective in Congo
The therapies saved roughly 90 percent of the patients who were newly infected, a turning point in the decades-long fight against the virus.
An Experimental Ebola Cure May Also Protect Against Nipah Virus
African green monkeys survived infection with the Nipah virus after they received remdesivir. The virus, a pandemic threat carried by bats, has killed dozens of people in Asia.
Global Health: Gilead Will Donate Truvada to U.S. for H.I.V. Prevention
The manufacturer will provide enough of the drug to supply 200,000 patients annually for more than a decade. Critics said it would not be enough to end the AIDS epidemic and questioned the company’s motives.